Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 5Pancreatic Neoplasms 2Ovarian Neoplasms 2Sarcoma 1Prostatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Follicular 1Fallopian Tube Neoplasms 1Estrogen Receptor Positive 1Colorectal Neoplasms 1Carcinoma, Endometrioid 1COVID-19 1Brain Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 5niraparib 2Taxes 2Paclitaxel 2Gemcitabine 2Cyclophosphamide 2Bevacizumab 2talazoparib 1sargramostim 1palbociclib 1oregovomab 1olaparib 1epacadostat 1dostarlimab 1birinapant 1atezolizumab 1aldesleukin 1Specimen Handling 1Sirolimus 1Selenium 1Polymerase Chain Reaction 1N-(5-(2,3-dihydrobenzofuryl)sulfonyl)-N'-(3,4-dichlorophenyl)urea 1Metformin 1Magnetic Resonance Spectroscopy 1Letrozole 1Injections 1Hyperthermic Intraperitoneal Chemotherapy 1Gene Expression Profiling 1Fulvestrant 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Fallopian Tube Neoplasms × palbociclib × Clear all
NCT04498520 2021-05-18

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

University of California, San Francisco

Phase 1 Withdrawn
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡